Lung Cancer ASCO 2024 Practice Changing Highlights – Discussion with Dr. Joshua Sabari

Share on facebook
Share on whatsapp
Share on twitter
Share on linkedin

In this episode of the Oncology Brothers podcast, we delved into the highlights from ASCO 2024, focusing on key studies in lung cancer. Dr. Joshua Sabari, a thoracic medical oncologist from NYU Langone Health, joined us to discuss the latest findings.

•⁠ ⁠LAURA Trial: Discussing the use of Osimertinib as a consolidation approach after chemoradiation in unresectable stage 3 non-small cell lung cancer patients with common EGFR mutation.
•⁠ ⁠MARIPOSA Study: Exploring the potential of Amivantamab and Lazertinib in common EGFR mutations.
•⁠ ⁠CROWN Study and other ALK inhibitors: Alectinib, Lorlatinib, and Brigatinib for metastatic non-small cell lung cancer.⁠
•⁠ ⁠ADRIATIC Study: Examining the use of Durvalumab after concurrent chemoradiation in limited-stage small cell lung cancer.
•⁠ ⁠PALOMA-3 Trial: Discussing subcutaneous Amivantamab vs. IV Amivantamab with Lazertinib

Overall, the episode emphasized the importance of precision medicine, the evolving landscape of treatment options in lung cancer, and the significance of multidisciplinary and patient-centered approaches in oncology practice.

Stay tuned for more highlights from ASCO 2024 across different cancer types in upcoming episodes. Thank you for listening to the Oncology Brothers podcast.

Subscribe Now


Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology